The aflibercept biosimilar, referencing Eylea, becomes the company’s fifth directly commercialized biosimilar in Europe, expanding access to ophthalmology treatments
On a full-year basis, revenue from operations for FY26 grew 18.9 percent year-on-year to Rs 827.87 crore compared to Rs 696.48 crore in FY25
As per National Health Accounts (NHA) estimates, government health expenditure rose steadily between 2013-14 and 2022-23, while out-of-pocket spending declined significantly
The company highlighted continued demand strength and pricing resilience despite global disruptions
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
Q4 FY26 PAT jumps 44% to Rs. 271 crore, supported by acquisitions, specialty expansion, and diagnostics momentum
Transition to a fermentation-based globally integrated CDMO platform
More than 450 public and private health technology solutions have integrated with the Ayushman Bharat Digital Mission ecosystem
Net profit stood at Rs. 921 crore for the quarter, while Europe revenues surged 30.2% YoY to Rs. 2,795 crore
Eye care major expands network to 288 facilities across 10 countries after adding 57 new centres during FY26
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
